Skye Bioscience, Inc. (SKYE) Operating income 2016–2025
Skye Bioscience, Inc. (SKYE) annual operating income history from SEC filings — each fiscal year as reported.
-$58.2MFY2025 · since FY2016: -$4.5M → -$58.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$58.2M | -92.6% |
| FY2024 | -$30.2M | +13.1% |
| FY2023 | -$34.7M | -89.7% |
| FY2022 | -$18.3M | -133.3% |
| FY2021 | -$7.8M | -24.8% |
| FY2020 | -$6.3M | +5.2% |
| FY2019 | -$6.6M | -41.3% |
| FY2018 | -$4.7M | -21.6% |
| FY2017 | -$3.9M | +13.7% |
| FY2016 | -$4.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SKYE financial trends
SKYE RevenueSKYE Net incomeSKYE Net marginSKYE Gross profitSKYE Gross marginSKYE Operating marginSKYE Operating cash flowSKYE Free cash flowSKYE Capital expendituresSKYE Return on equitySKYE Stock buybacksSKYE Dividends paidSKYE Total assetsSKYE Total liabilitiesSKYE Shareholders’ equitySKYE overview →